Enhancing ICU Candida spp. surveillance: a cost-effective approach focused on Candida auris detection
- PMID: 39554808
- PMCID: PMC11564180
- DOI: 10.3389/fcimb.2024.1463456
Enhancing ICU Candida spp. surveillance: a cost-effective approach focused on Candida auris detection
Abstract
Introduction: Candida auris is an emerging pathogen that represents a worldwide health problem due to its global expansion, multidrug resistance, and difficult laboratory identification. Among the risk factors for colonization/infection by C. auris, a stay in an intensive care unit (ICU) stands out. This prospective multicenter study aimed to monitor the trend of the local epidemiology of Candida spp. and unveil the prevalence of C. auris.
Methods: From 2020 to 2022, axillar/inguinal swabs were collected from adult patients at three points: upon admission (D1) and on the fifth (D5) and eighth (D8) days of their ICU stay. We employed culture-based screening methods combined with molecular techniques to identify Candida spp. down to the species level. Specific screening for Candida auris was conducted using a real-time PCR assay in combination with an improved selective culture medium, mannitol salt agar auris (MSAA). To validate the effectiveness of MSAA, a collection of reference C. auris strains representing the four major geographical clades was used.
Results: We enrolled 675 patients, and 355 Candida isolates were retrieved from the 988 swab samples collected. From those, 185/355 (52.1%) were identified as C. albicans and 170/355 (47.9%) as non-albicans Candida (NAC). MSAA medium showed a specificity of 94.8%, albeit C. auris was not detected in this cohort. The dynamics of Candida spp. colonization by ICU were significant at the three collection points. Upon admission, C. albicans was associated with the Beatriz Ângelo Hospital ICU (p=0.003) and C. tropicalis with the general Hospital Professor Doutor Fernando Fonseca (FFH) ICU (p=0.006). C. parapsilosis and C. lusitaniae were associated with FFH ICUs, with the general ICU at D5 (p=0.047) and surgical ICU at D8 (p=0.012). The dynamics of NAC colonization by ICU were significantly different at D1 (p=0.011), D5 (p=0.047), and D8 (p=0.012).
Conclusion: We developed and implemented a screening protocol for C. auris while uncovering the colonization patterns of Candida in the ICU. Our findings contribute to the optimization of overall patient management, ensuring that ICU protocols are resilient and adaptive to emerging fungal threats.
Keywords: Candida auris; Candida spp.; colonization; intensive care unit; mannitol salt agar auris; prevalence; surveillance.
Copyright © 2024 Nascimento, Inácio, Guerreiro, Diaz, Patrício, Proença, Toscano and Barroso.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Navigating the molecular landscape of Candida auris in a tertiary care setting in Eastern India.Indian J Med Microbiol. 2025 Mar-Apr;54:100814. doi: 10.1016/j.ijmmb.2025.100814. Epub 2025 Mar 6. Indian J Med Microbiol. 2025. PMID: 40044078
-
Yeast species in the respiratory samples of COVID-19 patients; molecular tracking of Candida auris.Front Cell Infect Microbiol. 2024 Apr 19;14:1295841. doi: 10.3389/fcimb.2024.1295841. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38707510 Free PMC article.
-
Emergence of the novel sixth Candida auris Clade VI in Bangladesh.Microbiol Spectr. 2024 Jul 2;12(7):e0354023. doi: 10.1128/spectrum.03540-23. Epub 2024 Jun 6. Microbiol Spectr. 2024. PMID: 38842332 Free PMC article.
-
Candida auris: A pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains.J Infect Chemother. 2019 Oct;25(10):743-749. doi: 10.1016/j.jiac.2019.05.034. Epub 2019 Jun 28. J Infect Chemother. 2019. PMID: 31257156 Review.
-
Candida auris Diagnostics: Identification and Screening.Clin Lab Med. 2025 Mar;45(1):101-110. doi: 10.1016/j.cll.2024.10.005. Epub 2024 Dec 12. Clin Lab Med. 2025. PMID: 39892930 Review.
Cited by
-
Addressing Critical Fungal Pathogens Under a One Health Perspective: Key Insights from the Portuguese Association of Medical Mycology.Mycopathologia. 2025 Aug 16;190(5):73. doi: 10.1007/s11046-025-00981-3. Mycopathologia. 2025. PMID: 40818022 Free PMC article.
References
-
- Boattini M., Pinto M. F., Christaki E., Fasciana T., Falces-Romero I., Tofarides A., et al. . (2023). Multicentre surveillance of candida species from blood cultures during the SARS-CoV-2 pandemic in southern Europe (CANCoVEU project). Microorganisms 11, 560. doi: 10.3390/microorganisms11030560 - DOI - PMC - PubMed
-
- Castanheira M., Deshpande L. M., Messer S. A., Rhomberg P. R., Pfaller M. A. (2020). Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. Int. J. Antimicrob. Agents 55, 105799. doi: 10.1016/j.ijantimicag.2019.09.003 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous